| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEFNCT06793371 | Cytokinetics | Phase 2 | Recruiting | 2026-09Estimated |
| RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset SeizuresNCT06798896 | SUPN | Phase 2 | Recruiting | 2027-08Estimated |
| Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia GravisNCT06799247 | Cartesian Therapeutics | Phase 3 | Active not recruiting | 2026-12-30Estimated |
| A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist UseNCT06804603 | Vanda Pharmaceuticals | Phase 2 | Completed | 2025-10-06Actual |
| A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety DisorderNCT06809179 | VTGN | Phase 2 | Completed | 2026-06-12Actual |
| A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)NCT06809595 | Definium Therapeutics US, Inc. | Phase 3 | Active not recruiting | 2026-08-13Actual |
| Long-Term Safety and Efficacy of Plozasiran in Adults With HypertriglyceridemiaNCT06822790 | Arrowhead Pharmaceuticals | Phase 3 | Active not recruiting | 2028-07Estimated |
| Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular EdemaNCT06825702 | KPRX | Phase 2 | Recruiting | 2026-11Estimated |
| VK2735 for Weight Management Phase 2 (Venture Oral Dosing)NCT06828055 | VKTX | Phase 2 | Completed | 2025-06-24Actual |
| ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective TrialNCT06828861 | AARD | Phase 3 | Terminated | 2026-05-07Actual |
| Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder CancerNCT06829823 | IBRX | Phase 2 | Not yet recruiting | 2026-11Estimated |
| Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive DisorderNCT06830044 | Vanda Pharmaceuticals | Phase 3 | Recruiting | 2028-03Estimated |
| A Phase 2 Study of MZE829 in Adults With APOL1 Kidney DiseaseNCT06830629 | Maze Therapeutics | Phase 2 | Recruiting | 2026-09Estimated |
| Open Label Safety Study of Tradipitant in Idiopathic and Diabetic GastroparesisNCT06836557 | Vanda Pharmaceuticals | Phase 3 | Completed | 2026-03-30Actual |
| A Study of TYRA-300 in Children With Achondroplasia: BEACH301NCT06842355 | TYRA | Phase 2 | Recruiting | 2030-01Estimated |
| A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)NCT06842498 | Kyntra Bio | Phase 2 | Recruiting | 2028-03-31Estimated |
| Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)NCT06843239 | Zura Bio Inc | Phase 2 | Active not recruiting | 2027-05Estimated |
| A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic HypersomniaNCT06843590 | Alkermes, Inc. | Phase 2 | Active not recruiting | 2026-11Estimated |
| Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque PsoriasisNCT06846541 | ALMS | Phase 3 | Active not recruiting | 2028-11Estimated |
| NE3107 in Adults With Neurological Symptoms of Long COVIDNCT06847191 | BIVI | Phase 2 | Completed | 2026-08-06Actual |
| Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic PainNCT06848348 | DWTX | Phase 2 | Active not recruiting | 2026-12Estimated |
| Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative ColitisNCT06850727 | Odyssey Therapeutics | Phase 2 | Recruiting | 2026-04Estimated |
| A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 WeeksNCT06851559 | PHAT | Phase 2 | Active not recruiting | 2026-09-11Actual |
| A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL)NCT06864104 | KARD | Phase 2 | Completed | 2026-01-12Actual |
| 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular DegenerationNCT06864988 | 4D Molecular Therapeutics | Phase 3 | Active not recruiting | 2027-06Estimated |
| An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101NCT06867107 | MSLE | Phase 2 | Recruiting | 2027-09-30Estimated |
| C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCVNCT06868264 | AVIR | Phase 3 | Completed | 2026-06-18Actual |
| A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)NCT06868628 | TLSA | Phase 2 | Recruiting | 2027-04-01Estimated |
| A Randomised, Double-blind, Placebo-controlled Phase 2a Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONP-002 in Adults With Mild Traumatic Brain InjuryNCT06870240 | OGEN | Phase 2 | Not yet recruiting | 2026-01-01Estimated |
| A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet SyndromeNCT06872125 | STOK | Phase 3 | Active not recruiting | 2027-03Estimated |
Trial details
- Registry ID
- NCT06793371
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06798896
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06799247
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06804603
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06809179
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06809595
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06822790
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06825702
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06828055
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06828861
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06829823
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06830044
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06830629
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06836557
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06842355
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06842498
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06843239
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06843590
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06846541
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06847191
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06848348
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06850727
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06851559
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06864104
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06864988
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06867107
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06868264
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06868628
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06870240
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06872125
- Phase
- Phase 3
Primary completion marks the end of data collection for the main study measures, not a results publication date.